Background Image and Headline States Background Image and Headline States Headline Inspired by Hope. Focused on Prevention. Powered by Innovation. Inline CTAs View Our Pipeline Learn About Us Block CTAs Image Image Phase 3 Study Protocol for NVX-CoV2373 in the U.S., Mexico and U.K. Image Image Positive UK Phase 3 Data for NVX-CoV2373, COVID-19 Vaccine Candidate, Published in The New England Journal of Medicine Image Image NanoFlu™ Positive Phase 3 Results and Update Eyebrow LATE-STAGE BIOTECHNOLOGY COMPANY Main Content About Novavax We are committed to delivering novel products that leverage our innovative proprietary recombinant nanoparticle vaccine technology to prevent a broad range of infectious diseases. We produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Image Call-to-action buttons See How Our Technology Works Never has our path forward been more clear or the need greater. Main Content Uniquely Qualified “We will draw on our experience in developing vaccine candidates for some of the world’s toughest viral threats and use the power of our innovative recombinant nanoparticle vaccine platform, fortified by our Matrix-M™ adjuvant, to address an urgent need—to reduce the human toll of vaccine-preventable diseases.” Stanley Erck President and Chief Executive Officer Novavax Eyebrow THREATS CONTINUALLY EMERGE AND EVOLVE Main Content An agile and determined team Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some of our greatest health challenges. Call-to-action buttons Learn About Our Science and Technology Learn about Recombinant nanoparticle platform Matrix-M™ adjuvant Partnerships Science and technology Relevant resources Investor relations Novavax in the News 11/15/2021 – Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373 11/10/2021 – Novavax Statement on UK and Mexico Phase 3 Clinical Trial Participants Considered Fully Vaccinated in the US 11/04/2021 – Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights 11/04/2021 – Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization 11/03/2021 – Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand View All Press Releases View Novavax in the News Main navigation ABOUT US OUR PIPELINE SCIENCE AND TECHNOLOGY RESOURCES CAREERS Utility navigation FOR INVESTORS Corporate Governance Stock Information Events SEC Filings Analyst Coverage Investor Relations Contact Annual Report Investor Presentation NEWS COVID-19 Candidate Updates Press Releases & Statements Novavax in the News Join the Press Release List Press Center Contact Us CONTACT US 21 Firstfield Road Gaithersburg, MD 20878 (240) 268-2000 SOCIAL Footer navigation Privacy Policy Terms and Conditions Pay Transparency Nondiscrimination Provision Purchase Order Terms and Conditions This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings. Accept